Xeris Biopharma Holdings Inc’s filing revealed that its insider Hecht Beth unloaded Company’s shares for reported $0.22 million on Mar 20 ’25. In the deal valued at $5.43 per share,40,000 shares were sold. As a result of this transaction, Hecht Beth now holds 1,353,510 shares worth roughly $6.88 million.
Then, Hecht Beth bought 40,000 shares, generating $205,600 in total proceeds.
Before that, Schmid John P. bought 4,515 shares. Xeris Biopharma Holdings Inc shares valued at $10,147 were divested by the Director at a price of $2.25 per share. As a result of the transaction, Schmid John P. now holds 25,200 shares, worth roughly $0.13 million.
Piper Sandler downgraded its Xeris Biopharma Holdings Inc [XERS] rating to a Neutral from a an Overweight in a research note published recently. A number of analysts have revised their coverage, including Oppenheimer’s analysts, who began to cover the stock in late March with a ‘”an Outperform”‘ rating. Craig Hallum began covering XERS with “Buy” recommendation on August 28, 2023. Jefferies started covering the stock on October 21, 2022. It rated XERS as “a Buy”.
Price Performance Review of XERS
On Tuesday, Xeris Biopharma Holdings Inc [NASDAQ:XERS] saw its stock fall -7.47% to $5.08. Over the last five days, the stock has lost -13.46%. Xeris Biopharma Holdings Inc shares have risen nearly 49.85% since the year began. Nevertheless, the stocks have risen 129.86% over the past one year. While a 52-week high of $6.07 was reached on 03/26/25, a 52-week low of $1.69 was recorded on 01/13/25. SMA at 50 days reached $4.21, while 200 days put it at $3.21.
Levels Of Support And Resistance For XERS Stock
The 24-hour chart illustrates a support level at 4.86, which if violated will result in even more drops to 4.64. On the upside, there is a resistance level at 5.40. A further resistance level may holdings at 5.72. The Relative Strength Index (RSI) on the 14-day chart is 54.64, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.02, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 62.66%. Stochastics %K at 58.62% indicates the stock is a holding.
How much short interest is there in Xeris Biopharma Holdings Inc?
A steep rise in short interest was recorded in Xeris Biopharma Holdings Inc stocks on 2025-03-14, growing by 0.94 million shares to a total of 11.21 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-14 was 10.27 million shares. There was a rise of 8.43%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on April 28, 2022 when Craig Hallum began covering the stock and recommended ‘”a Buy”‘ rating along with a $6.50 price target.
